PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.47 – $1.74
Volume139,759
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.94M
Price / earnings
—
Price / book
0.16×
Price / sales
0.4×
EV / sales
-0.67×
EV / EBITDA
0.29×
Profitability
Earnings per share
-$11.38
Return on assets
-9.99%
Return on equity
-109.82%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.65×
Current ratio
1.27×
Quick ratio
1.2×
Cash ratio
1×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELAB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.53M
$1.31M
$681.99K
$304.14K
$285.95K
$0
$0
$0
Cost of revenue
$1.93M
$920.92K
$451.52K
$196.85K
$207.92K
$0
$0
$0
Gross profit
$601.44K
$385.69K
$230.47K
$107.28K
$78.03K
$0
$0
$0
Selling, general and administrative
$2.53M
$2.25M
$3.33M
$1.53M
$1.87M
$702.53K
$1.1M
$974.99K
Research and development
$130.26K
$310.22K
$47.06K
$32.9K
$15K
$66.68K
$32.43K
$45K
Total operating expenses
$3.02M
$4.2M
$3.55M
$2.57M
$2.27M
$1.01M
$1.2M
$1.68M
Operating income
-$2.42M
-$3.82M
-$3.32M
-$2.47M
-$2.19M
-$1.01M
-$1.2M
-$1.68M
Interest expense
-$516.49K
-$641.23K
-$1.04M
-$339.77K
-$196.88K
-$2
-$10.47K
-$50.62K
Income before taxes
-$2.22M
-$2.96M
-$4.99M
-$2.97M
-$2.62M
-$579.49K
-$1.58M
-$1.72M
Income taxes
$0
$0
$0
$30.97K
$0
$0
$0
$0
Net income
-$2.24M
-$2.94M
-$4.97M
-$2.98M
-$2.59M
-$562.36K
-$1.61M
-$1.93M
Net income attributable to common shareholders
-$2.41M
-$2.94M
-$4.97M
-$2.98M
-$2.59M
-$562.36K
-$1.61M
-$1.93M
EBITDA
-$2.09M
-$3.51M
-$3.15M
-$2.41M
-$2.16M
-$1.01M
-$1.2M
-$1.67M
Basic earnings per share
-$3.01
-$6.03
-$111.75
-$782.91
-$1,178.16
-$379.81
-$2,480.27
-$5,868.96
Diluted earnings per share
-$3.01
-$6.03
-$111.75
-$782.91
-$1,178.16
-$379.81
-$2,480.27
-$5,868.96
Recent news
Company coverage with links to the original publishers.
PMGC Holdings Inc. (Nasdaq: ELAB) has executed a payment agreement with Longevity Health Holdings to convert its 5% net sales royalty from the January 2025 Elevai Skincare divestiture into scheduled monthly cash payments through August 2031. The agreement covers the 2025 royalty of $94,937 and all future royalty payments, with installments of $10,000 per month starting October 2026, interest accruing at WSJ Prime plus 1%, and mandatory prepayments triggered by capital events.
PMGC Holdings has entered into a non-binding term sheet with Australia-based Orbit2Orbit to conduct a spaceflight study evaluating NorthStrive Biosciences' muscle-preservation therapeutics (EL-22 and EL-32) in microgravity. The multi-part relationship includes a Mice2Space research collaboration, a U.S. aerospace manufacturing partnership with A&B Aerospace, and a planned CAD $200,000 strategic investment by PMGC in Orbit2Orbit ahead of its proposed Canadian Securities Exchange listing.
PMGC Holdings Inc. (Nasdaq: ELAB) confirmed compliance with Nasdaq's new Market Value of Listed Securities requirement with 8,095,835 shares outstanding as of July 29, 2026. The company is correcting inaccurate share count data from third-party providers and reported significant growth with total assets reaching $26.0 million (up 102% from year-end 2025) and cash of $14.4 million. The company recently completed the acquisition of A&B Aerospace, Inc. in May 2026.
NorthStrive Biosciences announced plans to initiate an independent flow cytometry (FACS) analysis program to characterize EL-22, an engineered Lactobacillus casei-based therapeutic candidate designed to preserve muscle during weight loss treatments. The study will quantify latent myostatin antigen expression on NorthStrive-manufactured cells and establish comparability against material previously manufactured by MOA Life Plus Co. Ltd., strengthening product identity and manufacturing consistency for future IND-enabling development.
NorthStrive Biosciences announced positive Phase III results from its AI-driven drug discovery program with Yuva Biosciences. Four small-molecule candidates identified by Yuva's MitoNova™ AI platform demonstrated statistically significant increases in ANT1 protein expression in primary human skeletal muscle cells, with dose-dependent induction ranging from +29% to +50%. The candidates will advance to confirmatory testing in more mature muscle models.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.